- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03369951
Minocycline Pharmacokinetics (ACUMIN)
A Phase IV Open-Label Pharmacokinetic Study of Minocycline for Injection Following a Single Infusion in Critically-Ill Adults (ACUMIN)
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Georgia
-
Decatur, Georgia, United States, 30033
- Emory Decatur Hospital - Clinical Trials - Immunology/Infectious Disease
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern Medicine - Department of Obstetrics and Gynecology - Division of Female Pelvic Medicine and Reconstructive Surgery
-
Chicago, Illinois, United States, 60611-2908
- Northwestern Memorial Hospital - ICU
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- University of Kentucky - UK Albert B Chandler Hospital
-
Louisville, Kentucky, United States, 40202-1622
- University of Louisville School of Medicine - Surgery
-
-
Michigan
-
Detroit, Michigan, United States, 48202-2608
- Henry Ford Health System - Henry Ford Hospital
-
Royal Oak, Michigan, United States, 48073-6700
- William Beaumont Hospital - Royal Oak Campus - Infectious Disease
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110-1010
- Washington University School of Medicine in St. Louis - Infectious Diseases
-
-
North Carolina
-
Durham, North Carolina, United States, 27701
- Duke University School of Medicine - Duke Clinical Research Institute - Duke Clinical Research Unit
-
Durham, North Carolina, United States, 27710
- Duke University Hospital - Duke Medicine Pavilion - MICU
-
Greenville, North Carolina, United States, 27834-9997
- East Carolina University - Infectious Diseases and Tropical/Travel Medicine Clinic
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- University of Cincinnati College of Medicine - Division of Infectious Diseases
-
Cleveland, Ohio, United States, 44106-1716
- Case Western Reserve University School of Medicine - Medicine - Infectious Diseases and HIV Medicine
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health and Science University - Division of Pulmonary and Critical Care Medicine
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213-3403
- University of Pittsburgh - Medicine - Infectious Diseases
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female > / = 18 years of age.
- Subject is in the ICU, or is being admitted to the ICU.
- Known or suspected Gram-negative infection for which the subject is receiving systemic antibiotics, and which was the reason for admission to the ICU, or reason for persistent need for ICU care.
- Expectation, in the judgment of the investigator, that the subject will remain admitted in the hospital for at least 48 hours following enrollment and that all study procedures will be completed.
- Expectation that intravenous access will be sufficient for drug infusion and either intravenous or arterial access will be sufficient to allow for all protocol required blood sampling to occur.
- The subject, or legally authorized representative (LAR), is able and willing to provide signed informed consent.
Exclusion Criteria:
- History of significant hypersensitivity or allergic reaction to tetracycline antibiotics.
- Receipt of oral or intravenous tetracycline class drugs within 7 days of enrollment (e.g., minocycline, tetracycline, tigecycline, doxycycline).
- Use of isotretinoin within 2 weeks of enrollment into the study.
Major surgery* within 48 hours prior to enrollment.
*Major surgery is defined as "the opening of either a body cavity or the mesenchymal barrier, using general anesthesia".
- Pregnant or breastfeeding women.
- Patient is being treated for intracranial hypertension.
Any condition that, in the judgment of the investigator, precludes participation because it could affect subject safety.*
*Subjects on, or who may be considered for Renal Replacement Therapy (RRT) during the study period are not excluded from participating in the study.
- Receipt of an investigational study product within 7 days prior to enrollment. Investigator discretion should be used when longer acting agents have been used in the previous 30 days.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Minocin® IV
200 mg minocycline hydrochloride IV infusion over approximately 60 minutes, n=50
|
Minocycline is a semisynthetic derivative of tetracycline and is indicated for the treatment of infections due to susceptible isolates of designated microorganisms.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Calculated Exposure Measures for Area Under the Curve 0 to 24 Hours After a Dose (AUC0-24)
Time Frame: Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, and 24 hours post dose
|
Total AUC0-24 is defined as area under the plasma minocycline concentration-time curve from 0 to 24 hours after a dose (milligrams x hours per liter (mg•hr/L)).
Patient dosing histories along with the individual post-hoc PK parameters were used to generate total concentration-time profiles.
The AUC0-24 was calculated using numerical integration using the data from 0 to 24 hours post-dose.
|
Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, and 24 hours post dose
|
Calculated Exposure Measures for Area Under the Curve From 0 to Infinity (AUC0-inf) Using Free-drug Concentrations
Time Frame: Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
Free-drug (unbound) AUC0-inf is defined as area under the plasma minocycline concentration-time curve from 0 to infinity after a dose (mg•hr/L).
Patient dosing histories along with the individual post-hoc PK parameters were used to generate unbound concentration-time profiles.
The AUC0-inf was calculated as Dose/CL.
|
Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
Calculated Exposure Measures for Area Under the Curve From 0 to Infinity (AUC0-inf) Using Total-drug Concentrations
Time Frame: Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
Total AUC0-inf is defined as area under the plasma minocycline concentration-time curve from 0 to infinity after a dose (mg•hr/L).
Patient dosing histories along with the individual post-hoc PK parameters were used to generate total concentration-time profiles.
The AUC0-inf was calculated as Dose/CL.
|
Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
Calculated Exposure Measures for Area Under the Curve to the Last Quantifiable Sample (AUC0-last)
Time Frame: Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
AUC0-last is defined as the area under the plasma minocycline concentration-time curve from 0 to the time of the last quantifiable sample after a dose (mg•hr/L).
This was not calculated for the primary outcome measure using the individual post-hoc PK parameters, however was calculated as part of the Non-compartmental analysis using the linear trapezoidal rule (linear up, log down calculation method).
|
Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
Calculated Exposure Measures for Maximum Plasma Concentration (Cmax)
Time Frame: Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
Total-drug Cmax is defined as the maximum plasma total minocycline concentration (mg/L) Patient dosing histories along with the individual post-hoc PK parameters were used to generate total concentration-time profiles.
Total Cmax was calculated for each simulated patient as the maximum simulated concentration.
|
Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
Calculated Exposure Measures for Plasma Concentration at 24 Hours After Dose (C24)
Time Frame: Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, and 24 hours post dose
|
Total-drug C24 is defined as total plasma minocycline concentration at 24 hours after a dose (mg/L).
Patient dosing histories along with the individual post-hoc PK parameters were used to generate total concentration-time profiles.
The total C24 were calculated for each simulated patient as the simulated concentration at 24 hours after dose.
|
Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, and 24 hours post dose
|
Individual Post-hoc PK Parameter Estimates for Area Under the Curve 0 to 24 Hours After a Dose (AUC0-24)
Time Frame: Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, and 24 hours post dose
|
Total AUC0-24 is defined as area under the plasma minocycline concentration-time curve from 0 to 24 hours after a dose (mg•hr/L).
Patient dosing histories along with the individual post-hoc PK parameters were used to generate total concentration-time profiles.
The AUC0-24 was calculated for each individual using numerical integration using the data from 0 to 24 hours post-dose.
Summary statistics were calculated using the individual post-hoc parameters and reported as calculated exposure measures.
|
Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, and 24 hours post dose
|
Individual Post-hoc PK Parameter Estimates for Area Under the Curve From 0 to Infinity (AUC0-inf) Using Free-drug Concentrations
Time Frame: Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
Free-drug (unbound) AUC0-inf is defined as area under the plasma minocycline concentration-time curve from 0 to infinity after a dose (mg•hr/L).
Patient dosing histories along with the individual post-hoc PK parameters were used to generate unbound concentration-time profiles.
The AUC0-inf was calculated for each individual as Dose/CL.
Summary statistics were calculated using the individual post-hoc parameters and reported as calculated exposure measures.
|
Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
Individual Post-hoc PK Parameter Estimates for Area Under the Curve From 0 to Infinity (AUC0-inf) Using Total-drug Concentrations
Time Frame: Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
Total AUC0-inf is defined as area under the plasma minocycline concentration-time curve from 0 to infinity after a dose (mg•hr/L).
Patient dosing histories along with the individual post-hoc PK parameters were used to generate total concentration-time profiles.
The AUC0-inf was calculated for each individual as Dose/CL.
Summary statistics were calculated using the individual post-hoc parameters and reported as calculated exposure measures.
|
Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
Individual Post-hoc PK Parameter Estimates for Area Under the Curve to the Last Quantifiable Sample (AUC0-last)
Time Frame: Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
AUC0-last is defined as the area under the plasma minocycline concentration-time curve from 0 to the time of the last quantifiable sample after a dose (mg•hr/L).
This was not calculated of the primary outcome measure for the population PK model, however was calculated as part of the Non-compartmental analysis using the linear trapezoidal rule (linear up, log down calculation method).
|
Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
Individual Post-hoc PK Parameter Estimates for Maximum Plasma Concentration (Cmax)
Time Frame: Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
Total-drug Cmax is defined as the maximum plasma total minocycline concentration (mg/L).
Patient dosing histories along with the individual post-hoc PK parameters were used to generate total concentration-time profiles.
The Individual post-hoc PK parameter estimate for total Cmax was calculated for each simulated patient as the maximum simulated concentration.
Summary statistics were calculated using the individual post-hoc parameters and reported as calculated exposure measures.
|
Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
Individual Post-hoc PK Parameter Estimates for Plasma Concentration at 24 Hours After Dose (C24)
Time Frame: Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, and 24 hours post dose
|
Total-drug C24 is defined as total Plasma minocycline concentration at 24 hours after a dose (mg/L).
Patient dosing histories along with the individual post-hoc PK parameters were used to generate total concentration-time profiles.
The Individual post-hoc PK parameter estimates for the total C24 were calculated for each simulated patient as the simulated concentration at 24 hours after dose.
Summary statistics were calculated using the individual post-hoc parameters and reported as calculated exposure measures.
|
Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, and 24 hours post dose
|
Magnitude of the Inter-individual Variability for Central Volume of Distribution (Vc)
Time Frame: Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
Vc was estimated from the structural two-compartment population PK model with constant fraction unbound (fub) which was used to characterize the total and unbound minocycline concentration-time data from ICU patients.
The model was developed on using nonlinear mixed effects modeling on PK time points collected up to 48 hours after a single-dose on Day 1. Magnitude of the inter-individual variability is expressed as percent coefficient of variation (%CV).
|
Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
Magnitude of the Inter-individual Variability for Distribution Clearance (CLd)
Time Frame: Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
CLd was estimated from the structural two-compartment population PK model with constant fraction unbound (fub) which was used to characterize the total and unbound minocycline concentration-time data from ICU patients.
The model was developed on using nonlinear mixed effects modeling on PK time points collected up to 48 hours after a single-dose on Day 1.
The standard error of the mean as fixed.
Magnitude of the inter-individual variability is expressed as percent coefficient of variation (CV%).
|
Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
Magnitude of the Inter-individual Variability for Free-drug Clearance (CL)
Time Frame: Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
Unbound minocycline concentration is determined as the product of total minocycline concentrations and fub.
Total minocycline concentrations and fub were estimated from the structural two-compartment population PK model with constant fraction unbound (fub) which was used to characterize the total and unbound minocycline concentration-time data from ICU patients.
Magnitude of the inter-individual variability is expressed as percent coefficient of variation (%CV).
|
Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
Magnitude of the Inter-individual Variability for Peripheral Volume of Distribution (Vp)
Time Frame: Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
Vp was estimated from the structural two-compartment population PK model with constant fraction unbound (fub), which was used to characterize the total and unbound minocycline concentration-time data from ICU patients.
The model was developed on using nonlinear mixed effects modeling on PK time points collected up to 48 hours after a single-dose on Day 1.
|
Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
Magnitude of the Inter-individual Variability for Total-drug Clearance (CL)
Time Frame: Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
CL was estimated from the structural two-compartment population PK model with constant fraction unbound (fub) which was used to characterize the total and unbound minocycline concentration-time data from ICU patients.
The model was developed on using nonlinear mixed effects modeling on PK time points collected up to 48 hours after a single-dose on Day 1. Magnitude of the inter-individual variability is expressed as percent coefficient of variation (%CV).
|
Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
Population Mean PK Parameter Estimates for Central Volume of Distribution (Vc)
Time Frame: Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
Vc was estimated from the structural two-compartment population PK model with constant fraction unbound (fub) which was used to characterize the total and unbound minocycline concentration-time data from ICU patients.
The model was developed on using nonlinear mixed effects modeling on PK time points collected up to 48 hours after a single-dose on Day 1.
|
Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
Population Mean PK Parameter Estimates for Distribution Clearance (CLd)
Time Frame: Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
CLd was estimated from the structural two-compartment population PK model with constant fraction unbound (fub), which was used to characterize the total and unbound minocycline concentration-time data from ICU patients.
The model was developed on using nonlinear mixed effects modeling on PK time points collected up to 48 hours after a single-dose on Day 1.
|
Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
Population Mean PK Parameter Estimates for Free-drug Clearance (CL)
Time Frame: Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
Unbound minocycline concentration is determined as the product of total minocycline concentrations and fub.
Total minocycline concentrations and fub were estimated from the structural two-compartment population PK model with constant fraction unbound (fub) which was used to characterize the total and unbound minocycline concentration-time data from ICU patients.
|
Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
Population Mean PK Parameter Estimates for Peripheral Volume of Distribution (Vp)
Time Frame: Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
Vp was estimated from the structural two-compartment population PK model with constant fraction unbound (fub), which was used to characterize the total and unbound minocycline concentration-time data from ICU patients.
The model was developed on using nonlinear mixed effects modeling on PK time points collected up to 48 hours after a single-dose on Day 1.
|
Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
Population Mean PK Parameter Estimates for Total-drug Clearance (CL)
Time Frame: Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
Total-drug clearance (CL) was estimated from the structural two-compartment population PK model with constant fraction unbound (fub), which was used to characterize the total and unbound minocycline concentration-time data from ICU patients.
The model was developed on using nonlinear mixed effects modeling on PK time points collected up to 48 hours after a single-dose on Day 1.
|
Pre-dose, immediately after infusion termination (~1 hour) and at 4, 12, 24, 36, and 48 post dose
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16-0011
- 2UM1AI104681-08 (NIH)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bacterial Infection
-
NovartisNovartis VaccinesCompletedBacterial Infection | Streptococcal Infection | Gram-positive Bacterial InfectionBelgium, Canada
-
Kirby InstituteNot yet recruitingInvasive Fungal Infections | Infection, Bacterial | Infection, Fungal | Injection Site Infection | Infection, Soft Tissue | Invasive Bacterial Infection
-
Centre Hospitalier Universitaire de BesanconUnknownAntibiotic Resistant Infection | Resistant Infection | Beta Lactam Resistant Bacterial Infection | Bacterial Resistance
-
Assistance Publique Hopitaux De MarseilleUnknown
-
University of DuhokNot yet recruiting
-
Melinta Therapeutics, Inc.Department of Health and Human ServicesCompletedBacterial InfectionUnited States, Bulgaria
-
University of OxfordCompletedPleural Infection | Pleural Infection BacterialUnited Kingdom
-
Jena University HospitalTerminatedSevere Bacterial InfectionBrazil, Colombia, Germany, Turkey
-
PfizerAllerganTerminatedGram-negative Bacterial InfectionUnited States, Hungary, Slovakia, Taiwan, India, Estonia, Greece, Italy
-
PfizerCompletedGram-negative Bacterial InfectionAustralia
Clinical Trials on Minocycline
-
Journey Medical CorporationDr. Reddy's Laboratories LimitedCompleted
-
State University of New York - Downstate Medical...RecruitingAsthma | Allergic RhinitisUnited States
-
Central South UniversityCompleted
-
OraPharmaCompleted
-
Johns Hopkins UniversityMakerere UniversityTerminatedHIV Infections | HIV-associated Cognitive ImpairmentUganda
-
Rempex (a wholly owned subsidiary of Melinta Therapeutics...Innovative Medicines Initiative; Universitätsklinikum KölnTerminatedRenal Insufficiency, Chronic | Healthy Subjects | Renal Insufficiency, AcuteGermany
-
University of PittsburghTerminated
-
Ain Shams Universityfaculty of pharmacy Tanta UniversityNot yet recruiting
-
University of South FloridaCompleted
-
Beijing Tiantan HospitalNeuroDawn Pharmaceutical Co., Ltd.RecruitingIschemic Stroke, AcuteChina